Core Insights - Izotropic Corporation has integrated a patent-pending radiation dose personalization feature into its IzoView Breast CT Imaging System, making it the first breast CT system to offer real-time customized radiation dosing [1][2] - The global breast imaging device market is projected to grow from USD $5.4 billion in 2024 to USD $8.69 billion by 2030, driven by trends in personalized medicine and rising breast cancer incidence [4] Company Developments - The optical pre-scan system captures a radiation-free image to calculate a personalized radiation dose based on each patient's breast size, enhancing operational efficiency and patient comfort [2][3] - IzoView is advancing through the U.S. FDA's Pre-Market Approval process and is preparing to initiate a pivotal clinical study in the U.S. while also aiming for a European CE Mark submission [5] Market Trends - The introduction of personalized radiation dosing aligns with a broader market shift towards personalized medicine, adapting screening protocols to individual risk factors [4] - The growth of the breast imaging market is supported by expanded reimbursement for supplemental screening in women with dense breast tissue and the adoption of technologies that enable individualized imaging protocols [4]

The breast imaging market is dominated by traditional mammography, digital breast tomosynthesis ("DBT", "3D mammography"), ultrasound, and MRI technologies, each of which has established clinical applications with well-known limitations. Mammography and DBT remain the primary 2D-based screening tools, yet their sensitivity decreases in approximately 50%+ of women with dense breast tissue1, where overlapping structures under breast compression can obscure lesions and tumours. Ultrasound is often used as a su ...